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Abstract
Background Pediatric regulations enacted in both Europe and the USA have disrupted the pharmaceutical industry, chal-
lenging business and drug development processes, and organizational structures. Over the last decade, with science and 
innovation evolving, industry has moved from a reactive to a proactive mode, investing in building appropriate structures and 
capabilities as part of their business strategy to better tackle the challenges and opportunities of pediatric drug development.
Methods The EFGCP Children’s Medicines Working Party and the IQ Pediatric working group have joined their efforts to 
survey their member company representatives to understand how pharmaceutical companies are organized to fulfill their 
regulatory obligations and optimize their pediatric drug development programs.
Results Key success factors and recommendations for a fit-for-purpose Pediatric Expert Group (PEG) were identified.
Conclusion Pediatric structures and expert groups were shown to be important to support optimization of the development 
of pediatric medicines.
Keywords Medicines for children · Pediatric medicines · Child · Drug development · Pediatric structures · Expert group
Introduction
Significant progress has been made since pediatric legis-
lation was first enacted in the USA two decades ago and 
with the implementation of the Pediatric Regulation in the 
European Union (EU) in 2007. In regions with pediatric-spe-
cific regulations (USA, EU, and Switzerland), it is routine In this article, ‘Pediatric Expert Group’ (PEG) is a term used as a common denominator when talking more generally about a 
pediatric structure used within a company or companies.
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for sponsors to meet with regulatory agencies to discuss 
pediatric plans for investigational products in their pipe-
lines. In addition, as drug developers have gained pediatric 
experience and expertise under these regulations, they have 
started to apply their knowledge to investigational products 
designed to address diseases primarily observed in pediatric 
populations. However, key complexities related to pediatric 
drug development have hindered optimal investment and 
operational implementation, including the scarcity of avail-
able pediatric patient populations, highly competitive thera-
peutic domains, and minimal financial returns on investment 
[1], which may be counterbalanced though by the 6-month 
reward. These complexities have led many sponsors to assess 
whether existing internal structures and processes tailored 
to address adult drug development were also fit for purpose 
to address the unique needs of pediatric drug development. 
Conducting a comprehensive internal evaluation of current 
practice in relation to the business needs is one way to assess 
whether centralizing pediatric expertise will address a drug 
developer’s organizational needs. To better tackle the chal-
lenges and opportunities of pediatric drug development, the 
pharmaceutical industry has invested in building appropriate 
structures and capabilities as part of their business strategy, 
i.e., namely to create a Pediatric Expert Group (PEG). There 
are two main drivers for a company when establishing a 
PEG: (1) as first priority, to develop and provide medicines 
wherever appropriate for pediatric patients to fulfill unmet 
medical needs and reduce off-label use and (2) to fulfill 
regulatory requirements. A PEG should not only enhance 
internal company functioning but also facilitate or establish 
interactions externally to enhance the quality and efficiency 
of pediatric medicines development, e.g., through external 
pediatric research networks, collaboration with academic 
institutions, public private partnerships (PPP), and patients’ 
organizations.
As part of their activities, the European Forum for Good 
Clinical Practice Children’s Medicines Working Party 
(EFGCP CMWP) surveyed its members to understand how 
the pharmaceutical industry is organized to support pediatric 
drug development. While drafting this article, a decision was 
taken to partner with the Pediatric Working Group/Clini-
cal Pharmacology Leader Group within the International 
Consortium for Innovation and Quality in Pharmaceutical 
Industry (the IQ CLPG pediatric working group). The sur-
vey method by CMWP utilized open text, while IQ utilized 
a semi-structured interview. The survey focused on how the 
PEGs in the CMWP and IQ member companies are struc-
tured, their remit, and role and responsibilities to ultimately 
provide recommendations for others who are considering 
establishing a PEG. In particular, questions focused on the 
inter-relation between pediatric and adult development, on 
whether or not pediatric portfolio management is under 
the remit of PEG, on the composition of the PEG, and the 
resources allocated to a PEG. There was good cross-func-
tional pediatric drug development representation since IQ 
interviewees were mainly clinicians and clinical pharma-
cologists, and CMWP were clinicians and regulatory person-
nel. Questions related to budget (e.g., to define whether there 
are advantages to have pediatric development included in the 
overall project budget or whether a PEG would have its own 
budget for pediatric development) were not included in the 
survey. In parallel to the work done by the CMWP, the IQ 
pediatric working group had set up interviews with its mem-
bers between June and November 2018. Both CMWP and IQ 
answers were then consolidated and used to inform Table 1. 
No further tool was applied. This article presents a summary 
of findings from the companies surveyed (Astellas, Astra-
Zeneca, Bayer, Boehringer-Ingelheim, Johnson & Johnson, 
Novartis, Pfizer, Roche/Genentech, and Sanofi), providing 
an overview of the variety of PEG structures established to 
date. Of note, only large and medium pharmaceutical com-
panies were surveyed since there are no small enterprises 
included in EFGCP and IQ pediatric groups. These findings 
can serve as recommendations for companies which have 
interest in establishing a PEG that is fit for purpose.
This article does not contain any studies with human or 
animal subjects performed by any of the authors.
Why is There a Need for a Specific Pediatric 
Structure?
Integration of pediatric aspects early in drug development 
has now become normal practice. Pediatric drug develop-
ment should be driven by the identified pediatric needs 
and must consider applicable regulatory requirements and 
recommendations [2]. With the implementation of sev-
eral pediatric policies in both Europe and the USA, and 
the strong support of various advocacy groups and of the 
pediatric community, pediatric research has made signifi-
cant progress [3, 4] over the last decade. To make safe and 
effective medicines available for the pediatric population, 
timely development of evidence on the proper use of prod-
ucts in pediatric patients of various ages is needed, taking 
into account not only regulatory guidelines [2] and clini-
cal recommendations, but also specific tools, trial designs, 
and methods [5], including the pharmaceutical design of 
pediatric formulations [6]. When developing medicines for 
pediatric patients, it is essential to identify the patient pop-
ulation and its specific characteristics and medical needs, 
the environment where the medicine is likely to be used 
(e.g., hospital or community), the existing knowledge, and 
the medicine’s acceptability/palatability [7–9]. Prelimi-
nary feasibility assessment of pediatric research networks 
conducted at an early stage in the pediatric development 
program, a key prerequisite to optimize trial operations and 
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execution, should systematically involve pediatric patients’ 
organizations and/or their caregivers [10, 11]. Their contri-
bution should lend credible and realistic insights regarding 
the feasibility of clinical trial conduct.
What are the Current Existing Models 
of Pediatric Expert Group Structures 
in Industry?
An important finding of the surveys is that numerous differ-
ent types of PEG infrastructures can support pediatric drug 
development. While structures differ, all companies sur-
veyed have acknowledged that the obligation to deliver pedi-
atric drug development programs, to address specific pedi-
atric medical needs, and to comply with the fast-evolving 
regulatory environment play an important role when estab-
lishing a PEG. While the companies surveyed have estab-
lished internal PEGs, the structures, roles and responsibili-
ties, and scope of work deviate substantially from company 
to company. The range of structures spans from a looser 
aggregation of subject matter experts who meet on an ad 
hoc basis to pediatric-specific departments with governance 
function. Accordingly, the mandate varies substantially, with 
some PEG having consultative capacity only (see Model 5 
in Table 1), while others have strategic ownership and full 
accountability for the pediatric development program (see 
Model 1 in Table 1).
While there are varied responsibilities of PEGs, there 
appears to be a consistent set of core functions that contrib-
ute to the PEG regardless of their structural make-up across 
companies. Besides medical (i.e., pediatricians) and regula-
tory expertise, clinical operations and clinical pharmacol-
ogy/pharmacometrics are usually represented in these PEGs.
A factor determining the size, mandate, and diversity of 
any PEG appears to relate to the company’s portfolio. A 
strong focus on oncology within the regulated pharmaceu-
tical industry may make certain models more efficient in 
addressing such therapeutic needs. In particular, while the 
European Medicines Agency (EMA) considers the broader 
condition to require pediatric cancer drug development, the 
U.S. Food and Drug Administration (FDA) will specifically 
require pediatric assessment in all New Drug Applications 
and Biologics License Applications submitted for adult 
oncology indication after 19 August 2020, in cases where 
the molecular target of the candidate molecule is substan-
tially relevant to cancers in childhood [12]. In such cases, a 
structure where the PEG is responsible for the program strat-
egy may be reasonable and useful (see Model 1 in Table 1).
For many companies, pediatric development is part of 
the overall product strategy driven by the adult project 
teams, and the key mandates of PEGs are a provision of 
their specific expert consultative advice on all aspects of 
pediatric development. This collaboration can be fostered 
with key external academic experts, pediatric research 
networks, advice from regulatory bodies, and/or external 
pediatric initiatives that serve to keep the PEG infrastruc-
ture up to date.
Common to all PEG structures, is a strong focus on medi-
cal functions, with expert pediatricians usually assigned 
per therapeutic area. For example, the Johnson & Johnson’s 
‘Child Health Innovation Leadership Department (CHILD)’ 
is a core pediatric department formed almost exclusively 
by pediatricians to guide the company’s pediatric portfolio 
(see Model 2 in Table 1). Besides the medical knowledge 
and expertise in pediatric indications, pediatricians may act 
as key contact to principal investigators, external clinical 
experts, pediatric hospitals, and medical societies, as well 
as pediatric research networks, and may be supported by 
other functions where needed, e.g., when it relates to policy 
or quantitative issues.
An iteration from the medical/pediatrician-led model is 
one including a regulatory expert as the chair of the PEG 
(see Model 3 in Table 1). However, when the regulatory 
expert is not the chair often multiple regulatory experts are 
part of the PEG. Across the industry, there is no consist-
ency in the given role of regulatory experts within the PEGs. 
Some may hold responsibility only for the pediatric strat-
egy and interactions with the regulatory authorities, while 
in other PEGs, regulatory experts are actively engaged in 
shaping regulatory policy both specific to pediatrics and to 
other crucial development topics including but not limited to 
access, pricing and reimbursement, or innovative analytics.
Expansion of the PEG by further functions such as clini-
cal pharmacologist, toxicologist, pharmaceutical develop-
ment (CMC), safety or legal experts, epidemiologist, as 
well as biostatistician ranges from full to almost full-time 
engagement in addition to routine project work, in order to 
deliver expertise for innovative study designs or to support 
extrapolation efforts. Pharmacometrician involvement in the 
PEG seems to be common practice to provide expertise in 
quantitative clinical pharmacology, clinical and nonclini-
cal Modeling & Simulation (M&S), bioinformatics, Health 
Technology Assessment, and payer’s evidence as well as in 
translational science.
All companies participating in the survey advised that 
clinical operations is an essential part of the PEG although 
the number of clinical operation experts and their level of 
dedication differed in whether they only support pediatric 
studies or are also responsible for adult clinical development 
programs.
While some PEGs include pediatric safety experts, oth-
ers rely on the expertise provided by the project team or 
included in specific safety knowledge groups, e.g., to provide 
expertise on the impact on the liver, cardiac, or immune 
system.
1080 Therapeutic Innovation & Regulatory Science (2020) 54:1076–1084
1 3
Quite often, nonclinical and CMC functions are included 
in the core PEG although they may serve as part of a sepa-
rate expert group, e.g., a nonclinical PEG, and functioning 
mostly through their respective project teams.
Epidemiology, real world data, and legal advice/patent 
experts can either be included in the core of a PEG or con-
sulted on an ad hoc basis.
When the responsibility for the strategic pediatric drug 
development plan remains with the adult project team, a 
common feature for most companies surveyed, some differ-
ences were noted in the use of PEG for counsel and advice. 
For most of the surveyed companies, it is mandatory to reach 
out to the PEGs early for discussion on the pediatric drug 
development strategy and review of regulatory documents 
such as Pediatric Investigation Plan (PIP), Pediatric Study 
Plan (PSP), or clinical study protocols (CSP); for others, 
such an approach is voluntarily. Similarly, in most compa-
nies surveyed PEGs are used to develop internal guidance 
documents, best practice standards, and template documents 
and to provide regulatory intelligence expertise to help pro-
ject teams designing their pediatric development program. 
Often, specific internal guidance documents (e.g., CMC, 
clinical pharmacology or M&S) are developed not only to 
ensure efficiency of process, but also to build functional 
capability and facilitate knowledge transfer.
Additionally, many companies noted that the point of 
contact for a specific function often leads a broader pedi-
atric-focused subject matter expert team (e.g., formulation 
expert team or clinical pharmacology expert team) that can 
be pulled in to address specific issues that may arise.
Simplifying the 5 Models of the Pediatric Group 
Structures
Based on companies’ feedback received by both the EFGCP 
CMWP and the IQ consortium, five different models of PEG 
structures were identified (Table 1) which can be easily re-
grouped into three distinct general types of models:
(1) Informal advisory pediatric networks: this type of net-
work requires a person who is dedicated to pediatric 
drug development and can identify other subject matter 
experts with various expertise, e.g., CMC, Nonclini-
cal, or Technical Development. In these PEGs, member 
involvement depends on the time allocated to provide 
support and advice on pediatric programs. When pedi-
atric strategy and programs are developed, it is com-
mon practice to create a pediatric drug development 
team with various persons from different functions. 
These persons can come from the informal PEG and 
vice versa and can become a PEG member as they gain 
pediatric experience (Model 5 of Table 1).
(2) Formal advisory pediatric networks: this type of net-
work requires subject matter experts working part or 
full time across all functions, which increases the qual-
ity of the scientific support provided. In this model, 
the individual project teams retain responsibility for 
the product’s strategic plan, whereas the PEG serves to 
provide consultation on pediatric-specific components 
to the product plan. Dependent on the company, these 
formal advisory networks may also provide a pediatric 
governance function, e.g., for the review of PIP, PSP 
or/and CSPs (Models 2, 3, and 4 of Table 1).
(3) Pediatric departments/team with the responsibility for 
pediatric programs: in this situation, pediatric knowl-
edge is consolidated and centralized within the com-
pany into one department with dedicated personnel 
from all contributing functions. Such a model (Model 1 
of Table 1) allows for a pediatric portfolio-based devel-
opment paradigm which manages the pediatric strategy 
separately from the overarching product strategy.
How to Define the Most Appropriate 
Fit‑for‑Purpose Pediatric Structure?
Defining the most appropriate pediatric structure for a com-
pany can only be done after an analysis of the potential effi-
ciency and productivity benefits each model could offer, in 
line with pipeline opportunities, and the existing scientific 
and regulatory environment.
Analysis of Efficiency and Productivity
When conducting a business review to assess the potential 
efficiency and productivity benefits for establishing a PEG 
in relation to pediatric program development needs, careful 
efforts should be undertaken to comprehensively analyze 
internal metrics, from discovery to product registration and 
beyond authorization. These may include but are not lim-
ited to therapeutic areas of interest and related modes of 
action and analysis of timelines: from discovery to entry 
into the clinic for the first in pediatric (FIP) patient; FIP to 
first pediatric marketing authorization; number of regulatory 
interactions with the same health authority (e.g., EMA) to 
agree on a pediatric program design; number of regulatory 
interactions with the same regulatory authority (e.g., EMA) 
to modify an agreed pediatric plan; and the rate of approval 
on first cycle submission for pediatrics. There should also 
be the need to look at pediatric-specific trial costs, includ-
ing but not limited to cost per patient in relation to adult 
studies; internal and external research organization (e.g., 
CRO) costs in relation to adult studies; and pharmaceuti-
cal development costs for age-appropriate formulations and 
their maintenance in the market post authorization. These 
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pediatric development costs should all be benchmarked 
internally between pediatric projects first (some may have 
benefited from the availability of experts such as pediatri-
cians in the project team or with external consultation) or 
against competitors who have ongoing development in the 
same therapeutic area and patient populations. Providing a 
clear picture of the existing efficiency and productivity (or 
lack thereof) related to the delivery of pediatric program 
development is considered essential to understand whether 
specific PEG structures may be needed and in which format. 
As contributors to this survey were all from medium to large 
size pharmaceutical companies, it may be difficult to infer 
from the survey results any recommendation for small size 
companies. If small size companies plan to include pedi-
atrics in their drug development program, they may either 
develop the program on their own, rely on external con-
sultants or on contract research organizations (CROs) with 
a pediatric center of excellence, or defer the start of their 
pediatric program for strategic development to future out-
licensing partners.
Analysis of Pipeline Opportunity
Targeted therapies research is rapidly revolutionizing how 
treatments for the most complex diseases can be developed, 
which has the potential to facilitate innovation targeted 
directly at pediatric diseases [13]. As precision medicine 
and tissue agnostic development approaches continue to 
emerge as key pipeline drivers, and with increase in dis-
ease pathophysiology knowledge, more opportunities may 
emerge in early phase development for investment in inno-
vation for rare or ultra-rare pediatric diseases. To accom-
modate this movement, companies need to ensure that they 
have considered its impact on the need for more extensive 
pediatric-specific expertise in basic science research and 
early phase translational development [14]. In addition, 
as global markets continue to shift and impact on invest-
ment in innovation, it is becoming increasingly important 
for a pediatric business case to consider common pediatric 
morbid-mortality in the third world e.g., with neonatal sep-
sis, childhood respiratory infections, diarrhea, malnutrition, 
or parasitic infection [15]. To be prepared for these new 
opportunities, a pediatric structure may be considered as a 
prerequisite to accommodate any new demands.
Analysis of the Scientific and Regulatory 
Environment
A good understanding of the environment and its opportuni-
ties can help address some of the well-known pediatric drug 
development challenges.
Collaboration with pediatric research networks can help 
overcome study feasibility or patient recruitment challenges 
by providing appropriate solutions. Pediatric research net-
works can also provide useful insights into national and local 
or legal and administrative requirements and can promote 
collaboration between other stakeholders like local regula-
tory authorities or patient groups. For these reasons, as per 
Article 44 of the EU Pediatric Regulation [16], the EMA had 
to develop, with the scientific support of its Pediatric Com-
mittee (PDCO), a European network of existing national and 
European networks, investigators, and centers with specific 
expertise in the performance of studies in the pediatric popu-
lation. The European Network of Pediatric Research at the 
EMA [17] (Enpr-EMA) which started its operations in May 
2010 currently includes 52 research network members with 
a variety of structures and levels of activity [18]; national 
and European disease-specific, age-specific, or multispe-
cialty networks, centers, and investigators with expertise 
in pediatrics and performing clinical studies in children. 
Over these last 10 years, the network has grown substan-
tially and has even expanded beyond Europe with networks 
in the USA, Canada, and Japan [19]. All of these networks 
represent a vast source of expertise [20] although most of 
them are still underutilized. A survey [21] carried out by the 
Enpr-EMA Working Group of PPPs in 2014 to increase net-
work visibility and understand industry expectations of net-
works resulted in 70 responses from a variety of companies, 
including large pharma, biotech, consultants, and Contract 
Research Organizations (CROs). A majority of respondents 
(66%) was already aware of Enpr-EMA although only 46% 
had already worked with Enpr-EMA or another research 
network. A large proportion (71%) of the respondents were 
from companies with a PEG, which may be seen as evidence 
that the collaboration with academic networks benefits from 
stable contacts within industry which can only be guaranteed 
when a pediatric structure exists. Generally, the respond-
ents highlighted that collaboration with research networks is 
very valuable and beneficial in providing different services 
to the pharmaceutical industry. The need for improvement 
was identified though to address the lack of consistency and 
uniformity in the network services; something Enpr-EMA 
has planned to focus on in the coming years. Since pediatric 
programs are by essence global, it is important to also con-
sider existing ex-EU research networks, such as the Interna-
tional Neonatal Consortium [22].
During recent years, there has been very meaningful 
improvements in clinical research, and in particular with 
patient engagement or public involvement. It is now widely 
accepted that stakeholders’ involvement in clinical research 
may have a significant impact on clinical trial conduct, 
resulting in more successful patient enrolment and retention 
[23]. An important evolution is that researchers and compa-
nies see the value and benefits of involving children, young 
people, and their families as partners in the design and deliv-
ery of clinical trials. Involving representatives of the targeted 
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patient populations in clinical research has many interesting 
benefits, including greater understanding of young people’s 
perspectives and disease-specific details and improvements 
in the study design and the quality of the research.
In May 2017, the European Young Person’s Advisory 
Group network [24] (eYPAGnet) was launched with the aim 
of empowering young people and families across Europe 
to contribute to pediatric health research. Currently, the 
eYPAGnet provides a single, centralized point of contact 
for the collaboration of the Young Person’s Advisory Group 
(YPAG) with the relevant working parties of the EMA, 
including Enpr-EMA and the PDCO, and with European Ini-
tiatives including the IMI conect4children (c4c) consortium 
or the Pediatric Clinical Research Infrastructure Network 
(PEDCRIN) [25, 26]. Involving young people in the drug 
development process from clinical trial design through to 
trial delivery (e.g., trial procedures, outcome measure selec-
tion, review of informed consent form or of patients’ diaries) 
has been seen to be of value.
Finally, through the assessment of pediatric multi-stake-
holder initiatives by a company, PEGs have been shown to 
provide value to project teams, since they offer an opportu-
nity to strengthen clinical research and develop solutions for 
important issues. The EU Innovative Medicines Initiative 
[27] (IMI) is a good example with its PPP projects aimed at 
accelerating the medicines development process, generating 
new scientific insights, and developing resources for open 
use by the research community. With the IMI c4c consor-
tium [28] launched in 2018, the expectation is to create a 
sustainable, integrated, pan-European collaborative pediatric 
network to speed up and facilitate the running of high-qual-
ity clinical trials in children while ensuring that the voices 
of young patients and their families are heard. This six-year 
project is one of the biggest initiatives funded by the Inno-
vative Medicines Initiative 2 Joint Undertaking (IMI2 JU).
Fit‑for‑Purpose Pediatric Structure
Companies, which have undertaken a detailed evaluation 
of efficiencies and productivity related to current pediat-
ric drug development that is responsive to regional regu-
latory requirements (e.g., EU Pediatric Regulation (EC) 
1901/2006, U.S. PREA) and have evaluated pipeline oppor-
tunities, can start mapping out appropriate options to address 
their organization’s pediatric drug development needs. In 
building the pediatric business case to obtain the company’s 
management support, it is important to construct a plan that 
reflects each company’s organizational culture as it is likely 
to inform the type and nature of pediatric expertise that will 
be best suited to influence pediatric-focused organizational 
changes. Therefore, we acknowledge that no one type of 
PEG may work for all companies. However, based on experi-
ence, it is strongly suggested to carefully consider a few key 
success factors (Table 2) to ensure that the pediatric struc-
ture is designed to meet organizational needs and support the 
integration of pediatric aspects early in drug development; 
in other words, a structure that is fit for purpose.
It is important to establish a cross-functional group 
for project team support and external network interface 
with a group Chair, at least partially dedicated to pedi-
atrics. Chairs, who are not dedicated full time, should 
be assigned a sufficient portion of their overall time (at 
least 20%) to ensure that the objectives of the PEG can 
be executed while meeting the needs of the organiza-
tion. The PEG should include representatives of the core 
Table 2.  Key Success Factors: Questions to Address for a Fit-for-Purpose PEG.
1. What organizational culture change is required for the PEG and the utility it may offer to be “bought into”? Is organizational information, 
advocacy, and training on pediatric needs required?
2. Is there a champion within the company’s management structure? Are they engaged and successful as an influencer?
3. What is the mandate for the individual PEG?
 – Delivering on efficiency in regional regulatory requirements? < – > Driving innovation for pediatric drug development?
 – Is the mandate region specific or is it intended to address global pediatric drug development needs?
4. What function and role will the PEG serve organizationally?
 – Internal consultancy to operationalize pediatric program development?
 – Will the PEG serve any governance function (e.g., sign off on strategic planning or protocol review)?
5. What composition is required to deliver on each organizational mandate? Clinical and clinical operations only or cross-functional program 
strategy including e.g., discovery and technical development?
6. Are there critical foundational start-up activities that are required (e.g., pediatric data standards, pediatric assent templates, pediatric proto-
col templates) before the PEG can focus its deliverables on the organizational mandate?
7. What is the resource commitment (personnel and financial) that is needed to credibly deliver the organizational mandate?
8. What are the deliverables the PEG can credibly deliver to the organization in 1 year, 3 years, 5 years, or 10 years?
9. What is the estimated impact organizationally (e.g., efficiency, quality) and societally?
10. Is there senior management support?
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functions (e.g., pediatricians, regulatory, clinical pharma-
cology, pre-clinical, CMC, patient safety, clinical opera-
tions experts) for whom their pediatric work should be 
a part of their individual objectives. Such a group needs 
to support internal initiatives such as training seminars, 
shared learning sessions, “best practice” documents (e.g., 
pediatrics vital signs, ECG thresholds, blood sampling and 
contraception guidelines, or consent/assent templates), and 
selected external pediatric activities (e.g., involvement in 
pediatric conferences or in PPPs). Finally, the PEG needs 
to have senior management endorsement demonstrating a 
commitment within the company mindset to support pedi-
atric plan development—not only as an obligation but also 
as an opportunity. In that context, it should be discussed 
how the adult program could be utilized to better inform 
the pediatric strategy. This could be done to support the 
development of an extrapolation concept, of an additional 
biomarker, or of pediatric clinical endpoints prior to their 
incorporation into the pediatric program. A PEG is an 
excellent expert resource for adult development teams 
to seek guidance when considering these pediatric needs 
early in a drug development program.
When building a PEG, defining a work plan with annual 
objectives and achievements, resource demands, as well as 
means for regular communication through Town Hall meet-
ings or via a dedicated share point site is important to dem-
onstrate the PEG’s utility.
Conclusion
More than 10 years after the implementation of the Pedi-
atric Regulation in Europe, it was interesting to survey the 
pharmaceutical industry to understand how companies are 
organized to tackle the challenges and opportunities of pedi-
atric clinical research. All respondents were representatives 
of large and medium pharmaceutical companies which 
have PEGs in place, but whose structures differ from one 
company to the other. All respondents agreed that it is of 
utmost importance to protect the rights of pediatric study 
participants, to optimize pediatric studies, to minimize the 
exposure of children to unnecessary clinical studies, and 
ultimately to increase the number of approved medicines 
for children. Based on this experience, we issue these recom-
mendations for companies that may need such a structure, 
highlighting that a key to success is a fit-for-purpose PEG. 
Such a structure may help to optimize company’s processes 
already in place to better address the development of pedi-
atric medicines and a rapidly evolving regulatory and sci-
entific framework.
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